Prosecution Insights
Last updated: November 12, 2026
Application No. 18/682,542

DNAZYMES TARGETING CELL WALL SYNTHESIS ENZYMES AND USES THEREOF

Non-Final OA §112
Filed
Feb 09, 2024
Priority
Aug 13, 2021 — provisional 63/232,992 +1 more
Examiner
GIBBS, TERRA C
Art Unit
1635
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
1E Therapeutics Ltd.
OA Round
1 (Non-Final)
64%
Grant Probability
Moderate
1-2
OA Rounds
74%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
617 granted / 969 resolved
+3.7% vs TC avg
Moderate +10% lift
Without
With
+10.4%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
56 currently pending
Career history
1016
Total Applications
across all art units

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This Office Action is a response to Applicant’s Response to Election/Restriction filed July 28, 2026. Claims 1-4, 15-17, 20, 22 and 24-36 are pending in the instant application. Election/Restrictions Applicant’s species election (without traverse) of a first substrate-binding domain and a second substrate-binding domain as set forth in SEQ ID NOs: 7 and 8, respectively in the reply filed on July 28, 2026 is acknowledged. The further species election (without traverse) of a DNAzyme nucleotide sequence as set forth in SEQ ID NO: 13 in the reply filed on July 28, 2026 is also acknowledged. The requirement is still deemed proper and is therefore made FINAL. Accordingly, claims 1-4, 15-17, 20, 22 and 24-36 have been examined on the merits as detailed below: Information Disclosure Statement Applicant’s information disclosure statement (IDS) filed May 8, 2024 is acknowledged. The submission is in compliance with the provisions of 37 CFR §1.97. Accordingly, the Examiner has considered the information disclosure statement, and a signed copy is enclosed herewith. Applicant’s IDS filed July 28, 2026 is acknowledged. The submission is in compliance with the provisions of 37 CFR §1.97. Accordingly, the Examiner has considered the information disclosure statement, and a signed copy is enclosed herewith. Drawings The Drawings filed on February 9, 2024 are acknowledged and have been accepted by the Examiner. Claim Objections Claims 1-4, 15-17, 20, 22 and 24-36 are objected to because of the following informalities: Claims 1-3 recite the phrase, “said method comprising administering a composition comprising a DNAzyme targeting a murG RNA transcript”. This is grammatically incorrect and should instead recite, “said method comprises administering a composition comprising a DNAzyme targeting a murG RNA transcript”. Claims 4, 15-17, 20, 22 and 24-36 are included in this objection due to their dependency therein. Claim 1 is further objected to because the last wherein clause incorrectly recites, “wherein said administration reduced the amount of the biofilm is said mammalian subject” instead of correctly reciting, “wherein said administration reduces the amount of the biofilm in said mammalian subject”. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2, 17, 25-30 and 33 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 2 recites the phrase, “said mammalian subject with a bacterial infection”. The claim lacks antecedent basis because the preamble makes reference to “a mammalian subject” and not “a mammalian subject with a bacterial infection”. Claims 25-30 are included in this rejection due to their dependency therein. Claims 17, 27 and 33 are indefinite because it is unclear whether parts following the term, “optionally” are actually a part of the claims. The term, “optionally” is ambiguous and confusing since the alternatives covered by the claims are not clear. See MPEP 2173.05(h) for further explanation. Claims Free of the Prior Art Claims drawn to the following methods are free of the prior art: A method of reducing an amount of a biofilm in a mammalian subject with a bacterial infection, said method comprises administering a composition comprising a DNAzyme targeting a murG RNA transcript, wherein said DNAzvme comprises (a) a first substrate-binding domain that is complementary to a first region of the transcript or partially complementarv to the first region of said transcript; and (b) a second substrate-binding domain that is complementary to a second region of said transcript or partially complementary to the second region of said transcript; wherein - the first substrate-binding domain comprises nucleic acid sequence 5'-GATCAGGTG-3' (SEQ ID NO: 7), and the second substrate-binding domain comprises nucleic acid sequence 5'-AACGGCAGG-3' (SEQ ID NO: 8); - the first substrate-binding domain comprises the nucleic acid sequence 5'-CTTGACCAG-3' (SEQ ID NO: 9), and the second substrate-binding domain comprises nucleic acid sequence 5'-GACTTCAGG-3' (SEQ ID NO: 10); - the first substrate-binding domain comprises nucleic acid sequence 5'-ATCTCGGCA-3' (SEQ ID NO: 11), and the second substrate-binding domain comprises nucleic acid sequence 5'-GCTGACGAC-3' (SEQ ID NO: 12); or - the first substrate-binding domain comprises nucleic acid sequence 5'-GGCGTTCTG-3' (SEQ ID NO: 31), and the second substrate-binding domain comprises nucleic acid sequence 5'-TCGTGGATC-3' (SEQ ID NO: 32), wherein administration of said DNAzyme reduces the amount of the biofilm in said mammalian subject with a bacterial infection. A method of increasing antibiotic susceptibility in a mammalian subject, said method comprises administering a composition comprising a DNAzyme targeting a murG RNA transcript, wherein said DNAzvme comprises (a) a first substrate-binding domain that is complementarv to a first region of the transcript or partially complementary to the first region of said transcript; and (b) a second substrate-binding domain that is complementary to a second region of said transcript or partially complementary to the second region of said transcript; wherein - the first substrate-binding domain comprises nucleic acid sequence 5'- GATCAGGTG-3' (SEQ ID NO: 7), and the second substrate-binding domain comprises nucleic acid sequence 5'-AACGGCAGG-3' (SEQ ID NO: 8); - the first substrate-binding domain comprises the nucleic acid sequence 5'-CTTGACCAG-3' (SEQ ID NO: 9), and the second substrate-binding domain comprises nucleic acid sequence 5'-GACTTCAGG-3' (SEQ ID NO: 10); - the first substrate-binding domain comprises nucleic acid sequence 5'-ATCTCGGCA-3' (SEQ ID NO: 11), and the second substrate-binding domain comprises nucleic acid sequence 5'-GCTGACGAC-3' (SEQ ID NO: 12); or - the first substrate-binding domain comprises nucleic acid sequence 5'- GGCGTTCTG-3' (SEQ ID NO: 31), and the second substrate-binding domain comprises nucleic acid sequence 5'-TCGTGGATC-3' (SEQ ID NO: 32), wherein administration of said DNAzvme increases antibiotic susceptibility in said mammalian subject. A method for inhibiting bacterial growth in a subject with a bacterial infection, said method comprises administering a composition comprising a DNAzyme targeting a murG RNA transcript, wherein said DNAzyme comprises (a) a first substrate-binding domain that is complementary to a first region of the transcript or partially complementary to the first region of said transcript; and (b) a second substrate-binding domain that is complementary to a second region of said transcript or partially complementary to the second region of said transcript; wherein - the first substrate-binding domain comprises nucleic acid sequence 5'-GATCAGGTG-3' (SEQ ID NO: 7), and the second substrate-binding domain comprises nucleic acid sequence 5'-AACGGCAGG-3' (SEQ ID NO: 8); - the first substrate-binding domain comprises the nucleic acid sequence 5'-CTTGACCAG-3' (SEQ ID NO: 9), and the second substrate-binding domain comprises nucleic acid sequence 5'-GACTTCAGG-3' (SEQ ID NO: 10); - the first substrate-binding domain comprises nucleic acid sequence 5'-ATCTCGGCA-3' (SEQ ID NO: 11), and the second substrate-binding domain comprises nucleic acid sequence 5'-GCTGACGAC-3' (SEQ ID NO: 12); or - the first substrate-binding domain comprises nucleic acid sequence 5'- GGCGTTCTG-3' (SEQ ID NO: 31), and the second substrate-binding domain comprises nucleic acid sequence 5'-TCGTGGATC-3' (SEQ ID NO: 32), wherein administration of said DNAzyme inhibits bacterial growth in said subject with a bacterial infection. Conclusion No claims are allowed at this time. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Terra C. Gibbs whose telephone number is 571-272-0758. The Examiner can normally be reached from 8 am - 5 pm M-F. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Ram Shukla can be reached on 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199. /TERRA C GIBBS/Primary Examiner, Art Unit 1635
Read full office action

Prosecution Timeline

Feb 09, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790615
COMPOSITIONS AND METHODS FOR SILENCING KRAS
3y 0m to grant Granted Nov 10, 2026
Patent 12781228
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
4y 1m to grant Granted Nov 03, 2026
Patent 12767948
Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
3y 10m to grant Granted Oct 20, 2026
Patent 12729381
METHODS AND COMPOSITIONS FOR INACTIVATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE (ITK)
3y 11m to grant Granted Sep 08, 2026
Patent 12709748
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
4y 3m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
64%
Grant Probability
74%
With Interview (+10.4%)
Low
PTA Risk
Based on 969 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month